Interaction between Tramadol and Aripiprazole
Major
Synergy
| ID | DDInter1841 and DDInter118 |
| Interaction |
Concomitant use of opioids such as tramadol with other central nervous system (CNS) depressants such as aripiprazole may result in hypotension, profound sedation, respiratory depression, coma, and death.Tramadol may prolong the QT interval, and while it is uncertain whether aripiprazole causes clinically significant prolongation of the QT interval, coadministration of multiple agents that can prolong the QT interval may theoretically result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.
adenoma
Amnesia
angioedema
Anxiety
Aching joints
Arthritis rheumatoid
AFIB
bipolar disorder
bruxism
carpal tunnel
More
|
| Management | The use of tramadol in conjunction with aripiprazole should generally be avoided. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. ECG monitoring may be advisable in some cases, such as in patients with a history of cardiac arrhythmias or congenital or family history of long QT syndrome. Particular care should be exercised in patients suspected to be at an increased risk of torsade de pointes. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. In addition, patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them. |
| References | |
| Alternative for Tramadol |
N02A
|
| Alternative for Aripiprazole | - |
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.